The Orexin System: A Potential Player in the Pathophysiology of Absence Epilepsy

Roberta Celli1, Gilles Van Luijtelaar2

  • 1I.R.C.C.S. Neuromed, Pozzilli, Italy.

Current Neuropharmacology
|December 16, 2021
PubMed
Abstract

Insights

Researchers investigated the orexin system

Area of Science:

  • Neuroscience
  • Epilepsy Research
  • Molecular Biology

Background:

  • Absence epilepsy is characterized by spike-and-wave discharges (SWDs) within the cortico-thalamo-cortical circuit.
  • The precise molecular mechanisms underlying absence epilepsy pathophysiology remain incompletely understood.
  • Wistar Albino Glaxo/Rij (WAG/Rij) rats serve as a validated animal model for absence epilepsy, exhibiting spontaneous SWDs.

Purpose of the Study:

  • To investigate the potential role of the orexin system in the pathophysiology of absence seizures.
  • To explore the orexin system as a potential therapeutic target for absence epilepsy.

Main Methods:

  • Orexin receptor type-1 (OX1) protein levels were quantified in the thalamus and somatosensory cortex of WAG/Rij rats and control Wistar rats.
  • Protein levels were assessed at two developmental stages: pre-symptomatic (25 days) and symptomatic (6-7 months).
  • Immunoblotting was employed to measure OX1 protein levels.

Main Results:

  • Reduced OX1 protein levels were observed in the thalamus and somatosensory cortex of symptomatic WAG/Rij rats compared to non-epileptic controls.
  • No significant differences in OX1 protein levels were found between pre-symptomatic WAG/Rij rats and controls.
  • These findings suggest a potential link between orexin system dysfunction and the development of absence epilepsy.

Conclusions:

  • The orexin system may be implicated in the pathophysiology of SWDs associated with absence epilepsy.
  • This research opens avenues for future investigations into the orexinergic system's role in absence epilepsy and its comorbidities.
  • Targeting the orexin system could represent a novel therapeutic strategy for absence epilepsy.

Related Concept Videos

Sleep-Wake Cycles01:24

Sleep-Wake Cycles

Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and  rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.8K
Neurotransmitters01:31

Neurotransmitters

Neurotransmitters are essential chemical messengers within the nervous system, facilitating the communication between neurons. These chemical messengers, varying in function and effect, are critical for sustaining various aspects of neurological health and emotional well-being.
1.7K
Narcolepsy01:07

Narcolepsy

Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
228
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
350
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
511
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
337